1. Home
  2. ESE vs IMVT Comparison

ESE vs IMVT Comparison

Compare ESE & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ESCO Technologies Inc.

ESE

ESCO Technologies Inc.

HOLD

Current Price

$263.27

Market Cap

7.1B

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$37.16

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESE
IMVT
Founded
1990
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
8.5B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
ESE
IMVT
Price
$263.27
$37.16
Analyst Decision
Strong Buy
Buy
Analyst Count
3
8
Target Price
$283.33
$33.00
AVG Volume (30 Days)
176.2K
1.1M
Earning Date
05-07-2026
05-28-2026
Dividend Yield
0.10%
N/A
EPS Growth
193.15
N/A
EPS
3.71
N/A
Revenue
$37,000,000.00
N/A
Revenue This Year
$21.42
N/A
Revenue Next Year
$6.99
N/A
P/E Ratio
$70.12
N/A
Revenue Growth
N/A
N/A
52 Week Low
$193.68
$14.58
52 Week High
$362.15
$45.42

Technical Indicators

Market Signals
Indicator
ESE
IMVT
Relative Strength Index (RSI) 34.76 36.23
Support Level $260.73 $23.66
Resistance Level $290.82 $41.22
Average True Range (ATR) 7.31 1.40
MACD 0.35 -0.42
Stochastic Oscillator 29.70 13.69

Price Performance

Historical Comparison
ESE
IMVT

About ESE ESCO Technologies Inc.

ESCO Technologies Inc sells engineered products and systems for utility, industrial, aerospace, and commercial applications. The firm operates in three segments: Aerospace & Defense (A&D), Utility Solutions Group (USG), and RF Test & Measurement (Test). The Aerospace and Defense segment designs and manufactures specialty filtration and naval products. The USG segment provides diagnostic testing solutions. The Test segment provides its customers with the ability to identify, measure, and contain magnetic, electromagnetic, and acoustic energy.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Share on Social Networks: